March 11 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T :
* TAKEDA CANADA SAYS POSITIVE RESULTS FOR ENTYVIO (VEDOLIZUMAB) VERSUS. HUMIRA (ADALIMUMAB) IN FIRST IBD STUDY TO COMPARE BIOLOGICAL AGENTS HEAD-TO-HEAD
* TAKEDA CANADA - ENTYVIO MET PRIMARY AND KEY SECONDARY ENDPOINTS IN PHASE 3B VARSITY STUDY
* TAKEDA - ENTYVIO SUPERIOR TO HUMIRA IN ACHIEVING CLINICAL REMISSION, MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS